glp-1 obesity drugs news today 2025 2024 was a record year for trials and is already poised to take over Study finds GLP-1 receptor agonists

Additional benefits included reductions in body mass index (BMI), blood pressure levels, HbA1c, and fasting blood glucose, observed after a minimum of six months of clinical follow-up (111)

Refunds are not issued for subscription fees, but you may receive a credit in the event of shipping errors

[DOI] [PMC free article] [PubMed] [Google Scholar] 24.[The glucagon-like peptide-1 receptor-agonist semaglutide] Boje AD, Juhl CR, Torekov SS, Madsbad S

The main adverse events reported in the liraglutide group were GI related, including nausea, vomiting, diarrhea and constipation

Currently, Saxenda (Liraglutide - NVO) and Wegovy (Semaglutide - NVO) are the two GLP-1 drugs approved for weight loss by the FDA

doi: 10.1080/14656566.2017.1323878